Molecular Partners AGMLLCF 25 Return-on-Tangible-Asset is -55.77% as of Mar. 2026. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.51 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,417 Biotechnology companies, Molecular Partners AG ranks worse than 60.41% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Molecular Partners AG's annualizedNet Income for the quarter that ended in Mar. 2026 was $-66.78 Mil. Molecular Partners AG's average total tangible assets for the quarter that ended in Mar. 2026 was $119.73 Mil. Therefore, Molecular Partners AG's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -55.77%.
The historical rank and industry rank for Molecular Partners AG's Return-on-Tangible-Asset or its related term are showing as below:
MLLCF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -51.15 Med: -27.49 Max: 54.27
Current: -51.15
During the past 13 years, Molecular Partners AG's highest Return-on-Tangible-Asset was 54.27%. The lowest was -51.15%. And the median was -27.49%.
MLLCF's Return-on-Tangible-Asset is ranked worse than 60.41% of 1417
companies
in the Biotechnology industry
Industry Median: -35.77
vs MLLCF: -51.15
Molecular Partners AG (OTCPK:MLLCF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Molecular Partners AG Return-on-Tangible-Asset Related Terms
Molecular Partners AG Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG Return-on-Tangible-Asset Chart
MLLCF vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Molecular Partners AG's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -55.77% mean?
Molecular Partners AG (MLLCF) has a Return-on-Tangible-Asset of -55.77% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Molecular Partners AG and its competitors. According to the industry distribution chart, Molecular Partners AG ranks #856 out of 1417 companies in the Biotechnology industry, placing it in the top 60.4%.
Is Molecular Partners AG's Return-on-Tangible-Asset too high?
Molecular Partners AG's current Return-on-Tangible-Asset is -55.77%. Based on the distribution chart, Molecular Partners AG ranks #856 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #856 out of 1417 companies for Return-on-Tangible-Asset. This places Molecular Partners AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Molecular Partners AG and its competitors. Molecular Partners AG's current Return-on-Tangible-Asset is -55.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.51, compared to a current price of $3.60 — trading 605.9% above its estimated fair value. The current Return-on-Tangible-Asset is -55.77%. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Return-on-Tangible-Asset is -55.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.60 is trading 605.9% above its estimated GF Value™ of $0.51.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
Return-on-Tangible-Asset: -55.77%
GF Value™: $0.51 vs. price of $3.60 (605.9% above fair value)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score
Get the complete analysis for MLLCF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
